Loading...
RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor
Although treatment with imatinib, which inhibits KIT and PDGFR, controls advanced disease in about 80% of gastrointestinal stromal tumor (GIST) patients, resistance to imatinib often develops. RACK1 (Receptor for Activated C Kinase 1) is a ribosomal protein that contributes to tumor progression by a...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4924716/ https://ncbi.nlm.nih.gov/pubmed/26893362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7426 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|